Abnormal growth and tumour formation are potential concerns with some cell products, and the FDA has received tumour reports involving unapproved regenerative products. This does not mean every stem cell treatment causes cancer, or that all tumours are malignant. Risk must be assessed for the cell type, preparation and use. Ask about testing and long-term follow-up. US FDA: regenerative medicine patient information.
On this page
Do not treat all cell products as the same
Ask the specialist which evidence supports the assessment of abnormal-growth risk for the proposed product. A report involving one preparation does not give a numerical risk for every other therapy. Equally, a small study with short observation cannot rule out rare or delayed problems. Obtain a plan for recording and reviewing later concerns.
Questions to take to a consultation
- What checks address product identity and abnormal growth?
- How long have comparable patients been followed?
- Who investigates and reports suspected adverse events?
Request clear written answers and discuss unresolved points with a clinician familiar with your history before committing to a product or procedure.
Related questions
- What are the negative side effects of stem cell therapy?
- What is a risk of using stem cells?
- Who is not a candidate for stem cell therapy?
Return to the FAQ index to browse all questions and the detailed decision guides.
Ask about an assessment
For questions about the review process, availability or a written estimate, message Thailand Stem Cell Clinic. Ask how to share records securely. An enquiry does not confirm eligibility or that a particular treatment is offered.
All FAQs · Treatment guides · Contact information
Sources and further reading
General information, not an individual medical recommendation. Prices, coverage, eligibility and authorisation require case-specific confirmation. Source links describe their own research and jurisdictions.